The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer

References

• Kosuri K, Muscarella P, BeKaii-Saab TS. Updates and controversies in the treatment of pancreatic cancer. Clin. Adv. Hematol. Oncol.4, 47–54 (2006).
   PubMedGoogle Scholar
• Sproul E. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am. J. Cancer34, 566–585 (1938).
   Google Scholar
• Ogren M, Bergqvist D, Wahlander K, Eriksson H, Sternby NH. Trousseau’s syndrome – what is the evidence? A population-based autopsy study. Thromb. Haemost.95, 541–545 (2006).
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb. Haemost.87, 575–579 (2002).
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J. Clin. Oncol.24, 484–490 (2006).
   PubMed Web of Science ®Google Scholar
• Blom JW, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur. J. Cancer42, 410–414 (2006).
   PubMed Web of Science ®Google Scholar
• Mandala M, Reni M, Cascinu S et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann. Oncol.18, 1660–1665 (2007).
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.25, 1960–1966 (2007).
   PubMed Web of Science ®Google Scholar
• Sgouros J, Maraveyas A. Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of Phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncol.47, 337–346 (2008).
   PubMed Web of Science ®Google Scholar
• Mandalà M, Falanga A, Piccioli A et al.; for the working group AIOM. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology. Crit. Rev. Oncol. Hematol.59, 194–204 (2006).
   PubMed Web of Science ®Google Scholar
• Nalluri SR, Chu D, Keresztes R et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA300, 2277–2285 (2008).
   PubMed Web of Science ®Google Scholar
• Falanga A, Rickels FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin. Thromb. Hemost.25, 173–182 (1999).
   PubMedGoogle Scholar
• Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. Selectin–mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J. Clin. Invest.112, 853–862 (2003).
   PubMed Web of Science ®Google Scholar
• Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest124, 58S–68S (2003).
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br. J. Surg.82, 1101–1104 (1995).
   PubMed Web of Science ®Google Scholar
• Nitori N, Yoshinori I, Nakanishi Y et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin. Cancer Res.11, 2531–2539 (2005).
   PubMed Web of Science ®Google Scholar
• Khorana AA, Ahrendt SA, Ryan CK et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin. Cancer Res.13, 2870–2875 (2007).
   PubMed Web of Science ®Google Scholar
• Abid Hussein MN, Meesters EW, Osmanovic N et al. Antigenic characterization of endothelial cell-derived microparticles and their detection ex vivo. J. Thromb. Haemost.1, 2434–2443 (2003).
   PubMed Web of Science ®Google Scholar
• Ghosh A, Li W, Febbraio M et al. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J. Clin. Invest.118, 1934–1943 (2008).
   PubMed Web of Science ®Google Scholar
• Muller I, Klocke A, Alex M et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J.17, 476–478 (2003).
   PubMed Web of Science ®Google Scholar
• Tilley RE, Holscher T, Belani R et al. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb. Res.122, 604–609 (2008).
   PubMedGoogle Scholar
• Del Conde I, Bharwani LD, Dietzen DJ et al. Microvesicle-associated tissue factor and Trousseau’s syndrome. J. Thromb. Haemost.5, 70–74 (2007).
   PubMed Web of Science ®Google Scholar
• Hron G, Kollars M, Weber H et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb. Haemost.97, 119–123 (2007).
   PubMed Web of Science ®Google Scholar
• Tesselaar ME, Romijn FP, Van Der Linden IK et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J. Thromb. Haemost.5, 520–527 (2007).
   PubMed Web of Science ®Google Scholar
• Zwicker JI, Liebman HA, Neuberg D et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin. Cancer Res.15, 6830–6840 (2009).
   PubMed Web of Science ®Google Scholar
• Prandoni P, Falanga A, Piccioli A. Cancer and venous thrombosis. Lancet Oncol.6, 401–410 (2005).
   PubMed Web of Science ®Google Scholar
• Wojtukiewicz MZ, Rucinska M, Zacharski LR et al. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb. Haemost.86, 1416–1420 (2001).
   PubMedGoogle Scholar
• Balzarotti M, Fontana F, Marras C et al. In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol. Res.16, 245–250 (2006).
   PubMedGoogle Scholar
• Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv. Exp. Med. Biol.313, 355–364 (1992).
   PubMedGoogle Scholar
• Yu J, Rak JW, Klement G, Kerbel RS. VEGF isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Res.62, 1838–1846 (2002).
   PubMed Web of Science ®Google Scholar
• Mousa SA, Linhardt R, Francis JL et al. Anti-metastatic effect of non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb. Haemost.96, 816–821 (2006).
   PubMed Web of Science ®Google Scholar
• Borsig L. Antimetastatic activities of heparins and modified heparins. Experimental evidence. Thromb. Res.2, S66–S71 (2010).
   Google Scholar
• Borsig L, Wong R, Feramisco J et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumour metastasis. Proc. Natl Acad. Sci. USA98, 3352–3357 (2001).
   PubMed Web of Science ®Google Scholar
• Debergh I, Van Damme N, Pattyn P et al. The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model. Br. J. Cancer102, 837–843 (2010).
   PubMed Web of Science ®Google Scholar
• Marchetti M, Vignoli A, Russo L et al. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb. Res.121, 637–645 (2008).
   PubMed Web of Science ®Google Scholar
• Khorana AA, Sahni A, Atland OG, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler. Thromb. Vasc. Biol.23, 2110–2115 (2003).
   PubMed Web of Science ®Google Scholar
• Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins – correlation with selectin inhibition, not antithrombotic activity. Clin. Cancer Res.11, 7003–7011 (2005).
   PubMed Web of Science ®Google Scholar
• Maraveyas A, Ettelaie C, Echrist H et al. Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion. Blood Coagulation Fibrinolysis21, 452–458 (2010).
   PubMedGoogle Scholar
• Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch. Intern. Med.166, 458–464 (2006).
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med.343, 1846–1850 (2000).
   PubMed Web of Science ®Google Scholar
• Zacharski LR, Henderson WG, Rickles FR et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer53, 2046–2052 (1984).
   PubMed Web of Science ®Google Scholar
• Chahinian AP, Propert KJ, Ware JH et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J. Clin. Oncol.7, 993–1002 (1989).
   PubMed Web of Science ®Google Scholar
• Maurer LH, Herndon JE 2nd, Hollis DR et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J. Clin. Oncol.15, 3378–3387 (1997).
   PubMed Web of Science ®Google Scholar
• Lebeau B, Chastang C, Berchot JM et al.; ‘Petites Cellules’ Group. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer74, 38–45 (1994).
   PubMed Web of Science ®Google Scholar
• Altinbas M, Coskun M, Er O et al. A randomized trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. J. Thromb. Haemost.2, 1266–1271 (2004).
   PubMed Web of Science ®Google Scholar
• Akl EA, van Doormaal FF, Barba M et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst. Rev.3, CD006652 (2007).
   Google Scholar
• Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer110, 1149–1161 (2007).
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin therapy with dalteparin, and survival in advanced cancer. The Fragmin Advanced Malignancy Outcome Study (FAMOUS). J. Clin. Oncol.22, 1944–1948 (2004).
   PubMed Web of Science ®Google Scholar
• Klerk CPW, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol.23, 2130–2135 (2005).
   PubMed Web of Science ®Google Scholar
• Sideras K, Schaefer PL, Okuno SH et al. Low-molecular-weight heparin in patients with advanced cancer: a Phase 3 clinical trial. Mayo Clin. Proc.81, 758–767 (2006).
   PubMed Web of Science ®Google Scholar
• Haas SK, Kakkar AK, Kemkes-Matthes B et al. Prevention of venous thromboembolism with low molecular weight heparin in patients with metastatic breast or lung cancer – results of the TOPIC studies. J. Thromb. Haemost.3(Suppl. 1), (2005) (Abstract OR059).
   Google Scholar
• Buller HR, Prins MH. Late breaking clinical trial: the effect of the low-molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the Inpact Investigators). J. Thromb. Hemost.7(Suppl. 2), (2009) (Abstract LB-MO-004).
   Google Scholar
• Agnelli G, Gussoni G, Bianchini C et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol.10, 943–949 (2009).
   PubMed Web of Science ®Google Scholar
• Lapierre F, Holme K, Lam L et al. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology6, 355–366 (1996).
   PubMed Web of Science ®Google Scholar
• Zacharski LR, Wojtukiewicz MZ, Costantini V et al. Pathways of coagulation/fibrinolysis activation in malignancy. Semin. Hemostas. Thromb.18, 104–116 (1992).
   PubMed Web of Science ®Google Scholar
• Nakchbandi W, Müller H, Singer MV, Löhr M, Nakchbandi IA. Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma. Scand. J. Gastroenterol.41, 1095–1104 (2006).
   PubMed Web of Science ®Google Scholar
• Sadoff L, Latino F. Complete clinical remission in a patient with advanced pancreatic cancer using mitomycin C-based chemotherapy: the role of adjunctive heparin. Am. J. Clin. Oncol.22, 187–190 (1999).
   PubMedGoogle Scholar
• von Delius S, Ayvaz M, Wagenpfeil S, Eckel F, Schmid RM, Lersch C. Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb. Haemost.98, 434–439 (2007).
   PubMed Web of Science ®Google Scholar
• Icli F, Akbulut H, Utkan G et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J. Surg. Oncol.95, 507–512 (2007).
   PubMed Web of Science ®Google Scholar
• Maraveyas A, Waters J, Roy R et al. Wedgwood gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised Phase IIB trial (the UK FRAGEM study). Proceedings of: ECCO. Eur. J. Cancer7, 362 (2009) (Abstract 6503).
   Web of Science ®Google Scholar
• Riess H, Pelzer U, Opitz B et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO 004. Proceedings of: ASCO. J. Clin. Oncol.28, 15s (2010) (Abstract 4033).
   PubMedGoogle Scholar